Post-marketing surveillance has included reports of: Irritability Mood changes Emotional flattening Anxiety However: These reports are uncommon They do not prove causation They often involve other contributing factors After reviewing these reports, both the FDA and European Medicines Agency concluded there is no clear causal linkbetween GLP-1 medications and serious mood or behavioral disorders, but they recommend clinical monitoring, especially in patients with a psychiatric history
Benefits: Natural and minimally invasive No downtime Enhances thickness and density Works synergistically with B12 supplementation
With Semaglutide, which works like a human gut hormone reducing appetite and hunger urges, you can lose up to 15% of your weight
Growing interest in GLP-1 has led many people to seek nutritional approaches that support pathways associated with this hormone
Cream boasts an advanced formula designed to provide optimal skin nourishment and whitening benefits
Why this matters for India: Generic entry could unlock a 5,000+ crore opportunity over the next 1215 months Prices may drop 3050% initially, and potentially 7075% over time #GLP-1 adoption in diabetes care is expected to rise sharply, adding 0.51% to IPM growth in FY27 Competition is intensifying, with 1015 players vying for share across India, regulated, and emerging markets Novo Nordisk has already launched Ozempic in India (Dec 2025), setting the stage for one of the most closely watched generic transitions in recent pharma history
